Anti–tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study

Summary Objective Rasmussen's encephalitis (RE) is a severe chronic inflammatory brain disease affecting one cerebral hemisphere and leading to drug‐resistant epilepsy, progressive neurologic deficit, and unilateral brain atrophy. Hemispherotomy remains the gold standard treatment but causes pe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Epilepsia (Copenhagen) 2016-06, Vol.57 (6), p.956-966
Hauptverfasser:	Lagarde, Stanislas, Villeneuve, Nathalie, Trébuchon, Agnès, Kaphan, Elsa, Lepine, Anne, McGonigal, Aileen, Roubertie, Agathe, Barthez, Marie‐Anne J., Trommsdorff, Valérie, Lefranc, Jérémie, Wehbi, Samer, Portes, Vincent, Laguitton, Virginie, Quartier, Pierre, Scavarda, Didier, Giusiano, Bernard, Milh, Mathieu, Bulteau, Christine, Bartolomei, Fabrice
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Adalimumab - therapeutic use Adolescent Adult Anti-Inflammatory Agents - therapeutic use Anti–tumor necrosis factor alpha Child Child, Preschool Cognitive science Cohort Studies Electroencephalography Encephalitis Encephalitis - drug therapy Epilepsy Female Gangrene Humans Infant Inflammation Male Neuropsychological Tests Neuroscience Pilot Projects Rasmussen encephalitis Statistics, Nonparametric Treatment Outcome Tumor Necrosis Factor-alpha - immunology Tumor necrosis factor-TNF Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!